Results 1 to 10 of about 8,632 (241)
Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers
Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, primarily their HCN4 subtype, are one of the promising targets for the development of cardioprotective agents.
G. V. Mokrov
doaj +1 more source
The hERG subtype potassium channel (Kv11.1) is one of the most important and one of the most studied biological targets for the creation of cardioprotective agents.
G. V. Mokrov
doaj +1 more source
Prenatally diagnosed fetal heart rhythm abnormalities—incidence, diagnosis and outcome
Backrounds: Fetal arrhythmias represent a significant cause of fetal morbidity and mortality and occur in approximately 1–3% of pregnancies. The unknown fetal arrhythmias are the cause of intrauterine fetal demise in as many as 3–10% of cases, as well as
Jelena Stamenković +7 more
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers
Cardiovascular diseases (CVD) are widespread and the leading cause of morbidity and mortality worldwide. Drugs for the treatment of CVD have been developed since the beginning of the 20th century.
G. V. Mokrov
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 6. Beta blockers
β-Blockers are one of the oldest classes of cardioprotectors used in the treatment of cardiovascular diseases. They reduce the heart rate, have a hypotensive effect, inhibit myocardial contractility and have antiarrhythmic properties.
G. V. Mokrov
doaj +1 more source
BACKGROUND: Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF). However, data on long-term clinical efficacy and safety of
Boldizsar Kovacs +4 more
doaj +1 more source
Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models
Several experimental studies have recently demonstrated that temporary autonomic block using botulinum toxin (BoNT/A1) might be a novel option for the treatment of atrial fibrillation.
David Sergeevichev +10 more
doaj +1 more source
BackgroundAntiarrhythmic drugs (AADs) are frequently prescribed following catheter ablation (CA) for atrial fibrillation (AF). However, to date, there is a lack of large-scale, multicenter controlled studies that have confirmed the efficacy of AADs in ...
Gang Chen +4 more
doaj +1 more source
Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large
O. D. Ostroumova, I. V. Goloborodova
doaj +1 more source
Background: Atrial fibrillation (AF) is a significant cause of morbidity and mortality with foreseeably increasing prevalence. While large animal models of the disease are well established but resource intensive, transgenic AF mouse models are not yet ...
Frank T. Stümpel +6 more
doaj +1 more source

